Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(15 sites)
United States
UCLA Medical Center, Los Angeles, California San Francisco Oncology Associates, San Francisco, California SCRI - Denver, Denver, Colorado University of Iowa, Iowa City, Iowa Cancer Hematology Centers Western Michigan, Grand Rapids, Michigan Columbia University Medical Center - Herbert Irving Pavilion, New York, New York Duke University Medical Center, Durham, North Carolina University of Cincinnati Cancer Center, Cincinnati, Ohio The Cleveland Clinic Foundation, Cleveland, Ohio Sidney Kimmel Cancer Center at Thomas Jefferson University, Philadelphia, Pennsylvania The Sarah Cannon Research Institute/Tennessee Oncology, Nashville, Tennessee The University of Texas MD Anderson Cancer Center, Houston, Texas Australia
Westmead Hospital, Sydney, New South Wales Queensland, Woolloongabba Canada
Princess Margaret Cancer Centre, Toronto, Ontario